(Discovery Toxicology/non-GLP)
Using in vivo models with a defined dosing schedule tracking endpoints clinical observations, body weight, hematology, clinical chemistry, and histopathology to determine maximum tolerated dose (MTD) and assess drug’s potential to cause adverse effects on various organs.